

Sangeetha M Reddy

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6415626/sangeetha-m-reddy-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

3,240
citations

16
h-index

28
g-index

28
ext. papers

4,648
ext. citations

13.9
avg, IF

4.47
L-index

#	Paper	IF	Citations
23	Abstract GS2-10: Nimbus: A phase 2 trial of nivolumab plus ipilimumab for patients with hypermutated her2-negative metastatic breast cancer (MBC). <i>Cancer Research</i> , 2022 , 82, GS2-10-GS2-10	10.1	0
22	Whole-genome sequencing of phenotypically distinct inflammatory breast cancers reveals similar genomic alterations to non-inflammatory breast cancers. <i>Genome Medicine</i> , 2021 , 13, 70	14.4	2
21	New horizons in imaging and surgical assessment of breast cancer lymph node metastasis. <i>Breast Cancer Research and Treatment</i> , 2021 , 187, 311-322	4.4	3
20	Mast Cells: A New Frontier for Cancer Immunotherapy. <i>Cells</i> , 2021 , 10,	7.9	10
19	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020 , 577, 549-555	50.4	654
18	Atezolizumab for the treatment of breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 151-158	3.5	24
17	Effect of Doxorubicin on Myocardial Bicarbonate Production From Pyruvate Dehydrogenase in Women With Breast Cancer. <i>Circulation Research</i> , 2020 , 127, 1568-1570	15.7	10
16	Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. <i>Nature Communications</i> , 2020 , 11, 1839	17.4	9
15	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. <i>Cancer Immunology Research</i> , 2019 , 7, 1025-1035	12.5	42
14	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , 2018 , 19, 181-193	21.7	168
13	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018 , 24, 1649-1654	50.5	377
12	Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma. <i>Cell</i> , 2018 , 175, 998-1013.e20	56.2	631
11	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017 , 9,	17.5	409
10	Interaction of molecular alterations with immune response in melanoma. <i>Cancer</i> , 2017 , 123, 2130-2142	6.4	18
9	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017 , 2,	6.2	82
8	Trastuzumab Increases HER2 Uptake and Cross-Presentation by Dendritic Cells. <i>Cancer Research</i> , 2017 , 77, 5374-5383	10.1	60
7	Impact of Statin Use on Outcomes in Triple Negative Breast Cancer. <i>Journal of Cancer</i> , 2017 , 8, 2026-2032	4.5	18

6	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016 , 6, 827-37	24.4	561
5	Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies. <i>Clinical Colorectal Cancer</i> , 2016 , 15, 37-46	3.8	23
4	Monitoring immune responses in the tumor microenvironment. <i>Current Opinion in Immunology</i> , 2016 , 41, 23-31	7.8	76
3	Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. <i>Current Oncology Reports</i> , 2016 , 18, 42	6.3	36
2	Targeting angiogenesis in metastatic breast cancer. <i>Oncologist</i> , 2012 , 17, 1014-26	5.7	19
1	Prognostic and Predictive Markers in Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2011 , 7, 267	1	1